Brepocitinib for Cutaneous Sarcoidosis

(BEACON Trial)

Recruiting at 3 trial locations

Overseen By Clinical Trial Administrator

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Priovant Therapeutics, Inc.

Disqualifiers: Lymphoproliferative disorder, Active malignancy, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 16 weeks

28 Participants Needed

Trial Summary

What is the purpose of this trial?

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Eligibility Criteria

This trial is for adults with cutaneous sarcoidosis, a skin condition causing red or purple bumps. Participants must meet certain health criteria to join, but specific inclusion and exclusion details are not provided.

Inclusion Criteria

CSAMI activity score ≥ 10

I have been diagnosed with skin sarcoidosis confirmed by a skin biopsy.

My weight is between 40kg and 130kg, and my BMI is under 40.

Exclusion Criteria

I have a history of cancer.

I currently have or recently had an infection.

I am at high risk for blood clots or heart disease.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive oral brepocitinib or placebo for cutaneous sarcoidosis

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Brepocitinib

Trial Overview The study tests the safety and effectiveness of an oral medication called Brepocitinib compared to a placebo in treating cutaneous sarcoidosis. It's likely that participants will be randomly assigned to either receive Brepocitinib or a placebo.

Participant Groups

Group I: Brepocitinib Dose Level 2 Experimental Treatment 1 Intervention

Group II: Brepocitinib Dose Level 1 Experimental Treatment 1 Intervention

Group III: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Priovant Therapeutics, Inc.

Lead Sponsor

Trials

4

Recruited

570+